Format

Send to

Choose Destination
Urol Oncol. 2015 Apr;33(4):166.e21-9. doi: 10.1016/j.urolonc.2014.11.021. Epub 2015 Feb 17.

Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.

Author information

1
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
2
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
3
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
4
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
5
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: JAKaram@mdanderson.org.

Abstract

PURPOSE:

Renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is an aggressive malignancy associated with a poor prognosis. Although existing literature focuses on patients presenting with metastatic disease, characteristics and outcomes for patients with localized disease are not well described. We aimed to evaluate postnephrectomy characteristics, outcomes, and predictors of survival in patients with sRCC who presented with clinically localized disease.

PATIENTS AND METHODS:

An institutional review board-approved review from 1986 to 2011 identified 77 patients who presented with clinically localized disease, underwent nephrectomy, and had sRCC in their primary kidney tumor. Clinical and pathologic variables were captured for each patient. Overall survival (OS) and recurrence-free survival (RFS) were calculated for all patients and those who had no evidence of disease (NED) following nephrectomy, respectively. Comparisons were made with categorical groupings in proportional hazards regression models for univariable and multivariable analyses.

RESULTS:

OS for the entire cohort (n = 77) at 2 years was 50%. A total of 56 (77%) patients of the 73 who has NED following nephrectomy experienced a recurrence, with a median time to recurrence of 26.2 months. On multivariable analysis, tumor stage, pathologically positive lymph nodes, and year of nephrectomy were significant predictors of both OS and recurrence-free survival. Limitations include the retrospective nature of this study and relatively small sample size.

CONCLUSIONS:

Long-term survival for patients with sRCC, even in clinically localized disease, is poor. Aggressive surveillance of those who have NED following nephrectomy is essential, and further prospective studies evaluating the benefit of adjuvant systemic therapies in this cohort are warranted.

KEYWORDS:

Nephrectomy; Renal cell carcinoma; Sarcomatoid

PMID:
25700975
PMCID:
PMC4664068
DOI:
10.1016/j.urolonc.2014.11.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center